 | |
| Clinical data | |
|---|---|
| Trade names | Pexion |
| Other names | AWD 131-138; ELB-138 |
| Routes of administration | Oral |
| ATCvet code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.220.751  |
| Chemical and physical data | |
| Formula | C13H14ClN3O2 |
| Molar mass | 279.72 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Imepitoin (INNTooltip International Nonproprietary Name), sold under the brand name Pexion, is an anticonvulsant which is used in veterinary medicine in Europe to treat epilepsy in dogs. It was recently approved in the United States. The drug also has anxiolytic effects. It was originally developed to treat epilepsy in humans, but clinical trials were terminated upon findings of unfavorable metabolic differences in smokers and non-smokers.
Imepitoin acts as a low-affinity (4,350–5,140 nM; relative to Ki = 6.8 nM for diazepam and Ki = 1.7 nM for clonazepam) partial agonist of the benzodiazepine site of the GABAA receptor (up to 12–21% of the maximal potentiation of diazepam, a full agonist of this site). It is the first partial agonist to be approved for the treatment of epilepsy. The drug also dose-dependently blocks voltage-gated calcium channels. It is not a benzodiazepine; instead, it is an imidazolone, and bears some structural similarities to hydantoin anticonvulsants like ethotoin and phenytoin.
See also
References
- ^ Rundfeldt C, Löscher W (2014). "The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy". CNS Drugs. 28 (1): 29–43. doi:10.1007/s40263-013-0129-z. PMID 24357084. S2CID 31627280.
- ^ Sanders S (29 April 2015). "Antiseizure Medications". Seizures in Dogs and Cats. Wiley. pp. 209–. ISBN 978-1-118-68970-7.
- ^ Thomas WB, Dewey CW (8 September 2015). "Seizures and Narcolepsy". In Dewey CW, da Costa RC (eds.). Practical Guide to Canine and Feline Neurology. Wiley. p. 259. ISBN 978-1-119-06204-2.
- ^ "Imepitoin". drugs.com. Archived from the original on 2019-06-17. Retrieved 2017-09-17.
| Anxiolytics (N05B) | |
|---|---|
| 5-HT1ARTooltip 5-HT1A receptor agonists | |
| GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators |
|
| Hypnotics | |
| Gabapentinoids (α2δ VDCC blockers) | |
| Antidepressants |
|
| Antipsychotics | |
| Sympatholytics (Antiadrenergics) |
|
| Others | |
| |
| GABAA receptor positive modulators | |
|---|---|
| Alcohols | |
| Barbiturates |
|
| Benzodiazepines |
|
| Carbamates | |
| Flavonoids |
|
| Imidazoles | |
| Kava constituents | |
| Monoureides | |
| Neuroactive steroids |
|
| Nonbenzodiazepines | |
| Phenols | |
| Piperidinediones | |
| Pyrazolopyridines | |
| Quinazolinones | |
| Volatiles/gases |
|
| Others/unsorted |
|
| See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators | |
| Ion channel modulators | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium |
| ||||||||||||||||||||||||
| Potassium |
| ||||||||||||||||||||||||
| Sodium |
| ||||||||||||||||||||||||
| Chloride |
| ||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||
| See also: Receptor/signaling modulators • Transient receptor potential channel modulators | |||||||||||||||||||||||||
 | This anticonvulsant-related article is a stub. You can help Misplaced Pages by expanding it. |